Why ECG is Critical Before Starting Psychiatric Medications

Starting a psychiatric medication is rarely a straightforward decision. Beyond diagnosis and dosage, a responsible clinician must also ask: is this patient’s heart ready for what this drug demands? That question is answered – at least in part – by a simple, non-invasive test: the electrocardiogram (ECG). Increasingly recognized as a standard step in psychiatric assessment, the ECG captures the electrical activity of the heart and can reveal hidden vulnerabilities that psychotropic medications might otherwise turn dangerous. Here’s why it matters, who needs it most, and what it does in a crisis.

How the ECG works and why psychiatry needs it 🔗

An ECG records the heart’s electrical impulses across time, tracing the sequence of events from the firing of the sinus node to the contraction and recovery of the ventricles. Each peak and interval on that tracing tells a story. In psychiatric practice, the most closely watched measurement is the QT interval – the stretch of time between the start of ventricular depolarization (the electrical discharge that triggers a heartbeat) and the end of repolarization (the recovery phase). When this interval is prolonged, the heart becomes vulnerable to a dangerous arrhythmia called torsades de pointes (TdP), a rapid, chaotic heartbeat that can deteriorate into sudden cardiac arrest.

The problem is that many commonly prescribed psychiatric medications – antipsychotics, tricyclic antidepressants, lithium, and certain mood stabilizers – directly interfere with the cardiac ion channels that regulate this interval. According to guidelines reviewed in Psychiatric Times, most cases of TdP occur when the QTc exceeds 500 milliseconds, and this threshold is widely used as a point above which cardiac risk substantially increases, even in the absence of other risk factors.

Psychotropic drugs delay cardiac repolarization by prolonging the QT interval, primarily because they bind cardiac potassium channels and block potassium efflux from cardiomyocytes. A prolonged QT can lead, in some cases, to a life-threatening polymorphic ventricular tachyarrhythmia – torsades de pointes – which may manifest as dizziness, syncope, or progress to ventricular fibrillation and sudden cardiac death.

Beyond the QT interval, the ECG also flags other concerns relevant to psychiatric prescribing: conduction abnormalities, signs of prior heart damage, and baseline arrhythmias that might worsen under medication. Psychiatrists must learn to recognize when abnormalities such as ventricular conduction delay or remote ischemia should preclude the prescription of a psychotropic medication entirely.

ECG for heart rhythm assessment before starting psychotropics 🔗

Different drug classes carry different cardiac risks, and an ECG before treatment helps establish a baseline against which future changes can be measured. Antipsychotics, particularly thioridazine and chlorpromazine, have long been associated with repolarization effects, and their propensity to prolong the QT interval is a known risk factor for torsade de pointes.

The risk is not uniform across all psychiatric medications. A comprehensive review published in PubMed found that among antidepressants, the tertiary tricyclic antidepressants – including imipramine, amitriptyline, and doxepin – appear to have the most pronounced cardiac impact. Secondary tricyclics such as nortriptyline and desipramine may affect children and the elderly more specifically. Notably, sertraline, citalopram, paroxetine, and bupropion showed no effect or even reductions in QTc across multiple studies.

When the QTc lengthens by 25% or more over baseline, the medication involved should be discontinued or the dose reduced. Electrolyte imbalances – particularly hypomagnesemia and hypokalemia – should also be corrected, as they independently prolong the QT interval and compound medication risk. This is why an ECG taken before treatment begins is so valuable: without a documented baseline, it becomes impossible to know whether a prolonged QTc was pre-existing or medication-induced.

Research has demonstrated how inconsistently this screening is actually performed. In a study of over 3,400 outpatients in the United Kingdom who were prescribed haloperidol, only 1.8% had an ECG at the start of treatment. An analysis conducted in Switzerland, however, found that routine ECG monitoring of all admitted psychiatric patients was cost-effective in reducing sudden cardiac deaths, especially in cases of polypharmacy and illicit substance use.

Who needs a pre-treatment ECG most urgently 🔗

While a baseline ECG is a sound precaution for most patients starting a QTc-prolonging psychiatric medication, certain groups face substantially elevated risk and should not begin treatment without one.

Smokers and patients with cardiovascular risk factors 🔗

Psychiatric patients as a population already carry disproportionate cardiovascular risk. Research published in the European Heart Journal found that psychiatric patients on psychotropic medications had a significantly higher prevalence of smoking, alcohol consumption, and illicit drug use compared to controls – all of which independently affect cardiac electrical function. Electrolyte abnormalities and psychotropic drug use were identified as significant predictors of QTc prolongation.

Smoking, in particular, promotes endothelial damage and accelerates coronary artery disease – conditions that increase the heart’s vulnerability to medication-induced arrhythmias. A person who smokes and begins a QTc-prolonging antipsychotic carries compounded risk: the drug stresses the heart’s repolarization while chronic tobacco use has already compromised the underlying tissue. An ECG taken before treatment begins can reveal whether this combination poses an unacceptable starting risk.

Heart attack survivors 🔗

A prior myocardial infarction leaves scarred myocardial tissue that is electrically unstable. This scar tissue can disrupt normal conduction pathways and create zones where arrhythmias are more likely to originate – making these patients far more susceptible to medication-induced rhythm disturbances. Research published in the Journal of the American Heart Association confirmed that psychotropic drugs have been shown to increase the risk of sudden cardiac death particularly during an acute coronary event, with acute ischemia identified as the most common mechanism of sudden cardiac death in psychiatric patients on antipsychotics.

Clinicians should factor in preexisting cardiac conditions when selecting among psychiatric medications – just as one might avoid ziprasidone in a patient with known cardiac disease, antipsychotic choice should be guided by an individual’s specific cardiac profile identified through ECG and clinical history.

Candidates for electroconvulsive therapy (ECT) 🔗

Electroconvulsive therapy places significant and sudden stress on the cardiovascular system. During the procedure, the induced seizure triggers a parasympathetic discharge, followed by a large sympathetic surge. The tonic phase of the ECT-induced seizure causes a 15- to 20-second parasympathetic discharge that can lead to bradyarrhythmias, including premature atrial and ventricular contractions, atrioventricular block, and asystole. The clonic phase then triggers a catecholamine surge producing tachycardia and hypertension.

These are not rare or theoretical events. Severe adverse cardiac events occur in between one in forty and one in fifteen patients administered ECT , making pre-procedure cardiac screening a clinical necessity, not a formality. The American Psychiatric Association states that before beginning a series of ECT treatments, a patient should receive a thorough psychiatric assessment, a medical examination, and often a basic blood test and ECG to check heart health.

Clinical guidelines specifically recommend ECG monitoring in high-risk patients with a history of cardiac disease, and flag that tricyclic antidepressants – sometimes co-prescribed with ECT – are known to increase the risk of cardiac adverse events during the procedure and anesthesia.

ECG in drug overdose emergencies 🔗

When a psychiatric patient arrives in an emergency setting following a suspected overdose, the ECG becomes one of the first and most critical diagnostic tools deployed. Many psychiatric medications cause characteristic, recognizable changes in the ECG during overdose – changes that directly guide treatment decisions.

Tricyclic antidepressant overdose 🔗

Tricyclic antidepressants (TCAs) remain among the most dangerous medications in overdose despite the availability of newer alternatives. Patients who attempt suicide with a TCA have a fatality rate of 70% if they do not reach a healthcare facility, but that rate drops to 3% if the patient reaches treatment in time.

The ECG is central to recognizing TCA toxicity quickly. Tricyclics cause cardiotoxic effects via blockade of myocardial fast sodium channels – producing QRS prolongation and a tall R wave in aVR – inhibition of potassium channels causing QTc prolongation, and direct myocardial depression.

The width of the QRS complex on the ECG directly predicts the severity of the clinical picture. In cases of TCA overdose, a QRS greater than 100 ms is predictive of seizures, and as many as 50% of patients with a QRS over 160 ms will experience ventricular arrhythmias. According to Medscape’s emergency toxicology reference, a normal QRS has a negative predictive value of 98.8% for ventricular dysrhythmias and 97.2% for metabolic acidosis in single-agent overdose cases, making it a powerful rule-out tool.

Crucially, ECG findings also drive immediate treatment. Overdose with signs of cardiotoxicity requires resuscitative management in a monitored area with airway management capability, IV access, high-flow oxygen, and IV sodium bicarbonate administration. The ECG is not just diagnostic here – it is the instrument that tells the clinician whether sodium bicarbonate is working, as narrowing of the QRS complex on repeat tracing confirms a response to treatment.

Antipsychotic and other psychiatric drug overdoses 🔗

Antipsychotic overdose may produce profound QT prolongation – sometimes exceeding 500 ms – creating high risk for torsades de pointes. ECG abnormalities like wide QRS complex and QT prolongation in poisoned patients indicate severe conditions that necessitate the implementation of cardiac monitoring systems. Clinical management guidelines recommend that once a patient with an abnormal initial ECG is identified, continuous cardiac monitoring should be started in all unwell patients, with fluid resuscitation for hypotension and sodium bicarbonate if cardiac arrhythmias are present.

For patients who survive and are medically stabilized, the work does not end at the cardiac monitor. Those who have presented with an intentional overdose require mental health assessment to manage the underlying cause of their presentation once medically stable. The ECG, in this sense, is the bridge between emergency physical care and the psychiatric care that follows.

Making ECG a routine part of psychiatric practice 🔗

The evidence is clear: ECG screening before initiating psychotropic treatment is not bureaucratic excess – it is sound clinical medicine. A clinical review in Psychiatric Services recommends that laboratory tests and an ECG be obtained for all patients before they begin any antipsychotic medication and at least yearly thereafter, with more frequent monitoring if risk factors are present.

Research confirms the stakes: ECG changes were observed in 15-20% of patients started on psychiatric medications, with antipsychotics accounting for the highest rate of change at 19.1%. That is not a negligible minority – it is roughly one in five patients whose cardiac profile is altered by the very treatment prescribed to help their mental health.

For the psychiatrist, the ECG is not just a cardiology tool borrowed for occasional use. It is a window into a patient’s physiological readiness for treatment, a safety check before potentially dangerous interventions like ECT, and a life-saving diagnostic instrument in the emergency room when someone has overdosed. Understanding how to read it – and when to act on it – is now considered core competency in modern psychiatric practice.

What do you think? Given that roughly one in five patients started on antipsychotic medications show ECG changes, should routine pre-treatment cardiac screening become a mandatory standard of care in all psychiatric settings worldwide – and what barriers might realistically stand in the way of implementing this? If you or someone you care for has been prescribed a long-term psychiatric medication, does knowing about the cardiac monitoring process change your perspective on what comprehensive mental health treatment should look like?

References

1. https://www.psychiatrictimes.com/view/abcs-cardiac-screening-electrocardiography
2. https://pubmed.ncbi.nlm.nih.gov/11996627/
3. https://www.ahajournals.org/doi/10.1161/JAHA.115.001894
4. https://www.psychiatry.org/patients-families/ect
5. https://emedicine.medscape.com/article/819204-workup
6. https://geekymedics.com/tricyclic-antidepressant-overdose/
7. https://psychiatryonline.org/doi/10.1176/appi.ps.52.5.607